Description
(Trifluoroacetate Form) Asp-Arg-Glu-A2pr(Nma)-Ala-Pro-Asn- Leu-Val-Tyr-Met-Val-Thr-Gly-A2pr(Dnp)- Pro-Ala-Ser-Asp-Glu-Ile-Lys-Arg-Leu-Pro-Gly-Asp-Ile-Gln-Val-Val-Pro-Ile-Gly-Val-Gly-Pro-Asn-Ala-Asn-Val-Gln-Glu-Leu-Glu-Arg-Ile-Gly-Trp-Pro-Asn-Ala-Pro-Ile-Leu-Ile-Gln-Asp-Phe-Glu-Thr-Leu-Pro-Arg-Glu-Ala-Pro-Asp-Leu-Val-Leu-Gln-Arg A2pr(Nma): N-beta-[2-(Methylamino)benzoyl]-2,3-Diaminopropionic Acid A2pr(Dnp): N-beta-(2,4-Dinitrophenyl)-2,3-Diaminopropionic Acid (M.W. 8314.30) C370H583N103O113S Fluorescence-Quenching Substrate for ADAMTS-13 K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata, Blood, 103, 607 (2004). (VWF73 Sequence) K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata, Br. J. Haematol., 129, 93 (2005). (FRETS-VWF73); This compound is produced by Peptide Institute, Inc. under license of the National Cardiovascular Center in Japan. Grade A